niacinamide has been researched along with Carcinoma, Papillary in 29 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma." | 9.15 | Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011) |
| " Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma." | 7.80 | Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014) |
| " We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib." | 7.79 | Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013) |
| "Sorafenib has clinically relevant antitumor activity in patients with progressive metastatic or locally advanced radio-iodine refractory differentiated thyroid cancer." | 6.77 | Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. ( Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW, 2012) |
| "Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma." | 5.15 | Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011) |
| "Sorafenib (BAY 43-9006) is an inhibitor of multiple-receptor tyrosine kinases involved in tumor growth and angiogenesis, which can be advantageously administered orally." | 3.85 | Sorafenib: rays of hope in thyroid cancer. ( Bernardini, R; Duntas, LH, 2010) |
| " Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma." | 3.80 | Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014) |
| "THERE WERE 62 PATIENTS (37 MEN, MEAN AGE: 61 years) treated with sorafenib (62%), sunitinib (22%), and vandetanib (16%) outside of clinical trials; 22 had papillary, five had follicular, five had Hürthle cell, 13 had poorly differentiated, and 17 had medullary thyroid carcinoma (MTC)." | 3.80 | Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. ( Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M, 2014) |
| " We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib." | 3.79 | Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013) |
| "Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies." | 2.80 | Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. ( Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F, 2015) |
| "Sorafenib has clinically relevant antitumor activity in patients with progressive metastatic or locally advanced radio-iodine refractory differentiated thyroid cancer." | 2.77 | Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. ( Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW, 2012) |
| "Sorafenib (Nexavar) is a multikinase inhibitor, which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumor cell [c-RAF (proto-oncogene serine/threonine-protein kinase), BRAF, (V600E)BRAF, c-KIT, and FMS-like tyrosine kinase 3] and in tumor vessels (c-RAF, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, and platelet-derived growth factor receptor β)." | 2.49 | Sorafenib and thyroid cancer. ( Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S, 2013) |
| "Medullary thyroid carcinoma has a worse prognosis, especially in patients with diffused cancers at the time of initial surgery." | 2.45 | Targeted molecular therapies in thyroid carcinoma. ( Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P, 2009) |
| "Treatment of patients with thyroid cancer is usually successful, and most patients are cured of the disease." | 2.42 | How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. ( Fagin, JA, 2004) |
| "Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection." | 1.48 | Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. ( Bonani, FA; Camargo, RY; Castro, G; Coura-Filho, GB; Danilovic, DLS; Freitas, RMC; Hoff, AO; Kulcsar, MA; Marui, S; Roitberg, FSR; Vanderlei, FAB, 2018) |
| "Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity." | 1.40 | Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. ( Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK, 2014) |
| "Here we present a man with pancreatic metastases from PTC, report our experience with sorafenib therapy, and discuss the role of endoscopic ultrasound (EUS)-guided biopsy in its diagnosis." | 1.38 | Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. ( Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS, 2012) |
| "Patients with progressive refractory thyroid cancer are potential candidates for clinical trials using tyrosine kinase inhibitors (TKIs), and a promising proportion of patients in these trials have achieved stable disease." | 1.37 | Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. ( Bousquet, G; Faugeron, I; Hindie, E; Lussato, D; Toubert, ME; Vercellino, L, 2011) |
| "Sorafenib is an orally administered multi-kinase inhibitor that has shown promise in the treatment of adults with advanced thyroid cancer, but it has not yet been studied in children with this disease." | 1.35 | The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. ( Clayman, GL; Herzog, CE; Sherman, SI; Waguespack, SG; Williams, MD, 2009) |
| " Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension." | 1.34 | Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. ( Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 20 (68.97) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Molina-Vega, M | 1 |
| García-Alemán, J | 1 |
| Sebastián-Ochoa, A | 1 |
| Mancha-Doblas, I | 1 |
| Trigo-Pérez, JM | 1 |
| Tinahones-Madueño, F | 1 |
| Danilovic, DLS | 1 |
| Castro, G | 1 |
| Roitberg, FSR | 1 |
| Vanderlei, FAB | 1 |
| Bonani, FA | 1 |
| Freitas, RMC | 1 |
| Coura-Filho, GB | 1 |
| Camargo, RY | 1 |
| Kulcsar, MA | 1 |
| Marui, S | 1 |
| Hoff, AO | 1 |
| Iyer, P | 1 |
| Mayer, JL | 1 |
| Ewig, JM | 1 |
| Shawa, H | 1 |
| Busaidy, NL | 2 |
| Schellingerhout, D | 1 |
| Habra, MA | 2 |
| Fallahi, P | 1 |
| Ferrari, SM | 1 |
| Santini, F | 1 |
| Corrado, A | 1 |
| Materazzi, G | 1 |
| Ulisse, S | 1 |
| Miccoli, P | 1 |
| Antonelli, A | 1 |
| Massicotte, MH | 1 |
| Brassard, M | 1 |
| Claude-Desroches, M | 1 |
| Borget, I | 1 |
| Bonichon, F | 2 |
| Giraudet, AL | 1 |
| Do Cao, C | 1 |
| Chougnet, CN | 1 |
| Leboulleux, S | 1 |
| Baudin, E | 1 |
| Schlumberger, M | 2 |
| de la Fouchardière, C | 1 |
| Pitoia, F | 1 |
| Dadu, R | 1 |
| Waguespack, SG | 2 |
| Sherman, SI | 3 |
| Hu, MI | 1 |
| Jimenez, C | 1 |
| Ying, AK | 1 |
| Bassett, RL | 1 |
| Cabanillas, ME | 1 |
| Ruan, M | 1 |
| Liu, M | 1 |
| Dong, Q | 1 |
| Chen, L | 2 |
| Worden, F | 1 |
| Fassnacht, M | 1 |
| Shi, Y | 1 |
| Hadjieva, T | 1 |
| Gao, M | 1 |
| Fugazzola, L | 1 |
| Ando, Y | 1 |
| Hasegawa, Y | 1 |
| Park, DJ | 1 |
| Shong, YK | 1 |
| Smit, JW | 2 |
| Chung, J | 1 |
| Kappeler, C | 1 |
| Meinhardt, G | 1 |
| Brose, MS | 1 |
| Wirth, LJ | 1 |
| Droz, JP | 1 |
| Hofmann, M | 1 |
| Bastholt, L | 1 |
| Martins, RG | 1 |
| Licitra, L | 1 |
| Eschenberg, MJ | 1 |
| Sun, YN | 1 |
| Juan, T | 1 |
| Stepan, DE | 1 |
| Schlumberger, MJ | 1 |
| Henderson, YC | 1 |
| Ahn, SH | 1 |
| Kang, Y | 1 |
| Clayman, GL | 2 |
| Chowdhury, S | 1 |
| Choueiri, TK | 2 |
| Williams, MD | 1 |
| Herzog, CE | 1 |
| Romagnoli, S | 1 |
| Moretti, S | 1 |
| Voce, P | 1 |
| Puxeddu, E | 1 |
| Fagin, JA | 2 |
| Tuttle, RM | 1 |
| Pfister, DG | 1 |
| Duntas, LH | 1 |
| Bernardini, R | 1 |
| Shen, Y | 1 |
| Luo, Q | 1 |
| Yu, Y | 1 |
| Lu, H | 1 |
| Zhu, R | 1 |
| Toubert, ME | 1 |
| Vercellino, L | 1 |
| Faugeron, I | 1 |
| Lussato, D | 1 |
| Hindie, E | 1 |
| Bousquet, G | 1 |
| Nowicki, TS | 1 |
| Moscatello, AL | 1 |
| Shin, E | 1 |
| Schantz, S | 1 |
| Tiwari, RK | 1 |
| Geliebter, J | 1 |
| Cabrejas Gómez, Mdel C | 1 |
| Aguillo Gutiérrez, E | 1 |
| Altemir Trallero, J | 1 |
| Ocón Bretón, J | 1 |
| Lázaro Sierra, J | 1 |
| Alzahrani, AS | 1 |
| AlQaraawi, A | 1 |
| Al Sohaibani, F | 1 |
| Almanea, H | 1 |
| Abalkhail, H | 1 |
| Matsuse, M | 1 |
| Mitsutake, N | 1 |
| Tanimura, S | 1 |
| Ogi, T | 1 |
| Nishihara, E | 1 |
| Hirokawa, M | 1 |
| Fuziwara, CS | 1 |
| Saenko, VA | 1 |
| Suzuki, K | 1 |
| Miyauchi, A | 1 |
| Yamashita, S | 1 |
| Schneider, TC | 1 |
| Abdulrahman, RM | 1 |
| Corssmit, EP | 1 |
| Morreau, H | 1 |
| Kapiteijn, E | 1 |
| Cohen, SM | 1 |
| Mukerji, R | 1 |
| Timmermann, BN | 1 |
| Samadi, AK | 1 |
| Cohen, MS | 1 |
| Salvatore, G | 1 |
| De Falco, V | 1 |
| Salerno, P | 1 |
| Nappi, TC | 1 |
| Pepe, S | 1 |
| Troncone, G | 1 |
| Carlomagno, F | 1 |
| Melillo, RM | 1 |
| Wilhelm, SM | 1 |
| Santoro, M | 1 |
| Plantade, A | 1 |
| Elson, P | 1 |
| Negrier, S | 1 |
| Ravaud, A | 1 |
| Oudard, S | 1 |
| Zhou, M | 1 |
| Rini, BI | 1 |
| Bukowski, RM | 1 |
| Escudier, B | 1 |
| Procopio, G | 1 |
| Verzoni, E | 1 |
| Gevorgyan, A | 1 |
| Mancin, M | 1 |
| Pusceddu, S | 1 |
| Catena, L | 1 |
| Platania, M | 1 |
| Guadalupi, V | 1 |
| Martinetti, A | 1 |
| Bajetta, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer[NCT00984282] | Phase 3 | 417 participants (Actual) | Interventional | 2009-10-15 | Completed | ||
| A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer[NCT00121628] | Phase 2 | 184 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma[NCT01813136] | Phase 2 | 168 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Sorafenib AUC(0-12h),ss (area under the concentration time curve from time 0 to 12 hours at steady state) was estimated from the steady state plasma concentration. (NCT00984282)
Timeframe: A single pharmacokinetic plasma sample was collected at steady state (after 14 days of uninterrupted, unmodified sorafenib dosing)
| Intervention | mg*h/L (Geometric Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 75.4 |
Disease control rate was defined as the proportion of subjects whose best response was complete response (CR), partial response (PR), or stable disease (SD). Per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, CR and PR were to be confirmed by another scan at least 4 weeks later; SD had to be documented at least 4 weeks after date of randomization. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. SD = steady state of disease which is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 86.2 |
| Placebo | 74.6 |
Duration of response was defined as the time from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression or death (if death occurred before progression was documented). CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 309 |
| Placebo | NA |
Overall survival was defined as the time (days) from date of randomization to date of death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Since the median value could not be estimated due to censored data, the percentage of participants who died is presented. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (30 AUG 2017), study duration approximately eight years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 52.7 |
| Placebo | 54.8 |
PFS=time from randomization to first observed disease progression (radiological according to central assessment or clinical due to bone irradiation, whichever is earlier), or death due to any cause, if death occurred before progression. Progression was assessed by RECIST criteria, version 1.0, modified for bone lesions. PFS for participants without disease progression or death at the time of analysis or unblinding were censored at the last date of tumor assessment before unblinding. Participants with no tumor evaluation after baseline were censored at Day 1. PD (Progression Disease)=At least a 20% increase in sum of longest diameters (LD) of measured lesions taking as reference the smallest sum LD on study since the treatment started or the appearance of 1 or more new lesions. New lesions also constituted PD. In exceptional circumstances, unequivocal progression of a nonmeasured lesion may have been accepted as evidence of disease progression in participants with measurable disease. (NCT00984282)
Timeframe: Final analysis to be performed when approximately 267 progression-free survival events (centrally assessed) had occurred, study duration approximately three years
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 329 |
| Placebo | 175 |
Response rate was defined as the proportion of subjects whose best response was CR or PR. Per RECIST, CR and PR was to be confirmed by another scan at least 4 weeks later. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
| Intervention | Percentage of participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 12.24 |
| Placebo | 0.5 |
Time to progression was defined at the time (days) from randomization to progression (based on central assessment [radiological and clinical progression due to bone irradiation]) (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 337 |
| Placebo | 175 |
The magnitude of change from baseline in target lesion size in evaluable participants with scans was determined. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Reduction ≥ 30% | Reduction ≥ 20% but < 30% | Reduction ≥ 10% but < 20% | Reduction > 0% but < 10% | Growth ≥ 0% | Not assessed | |
| Placebo | 1.0 | 1.5 | 3.5 | 21.9 | 62.7 | 9.5 |
| Sorafenib (Nexavar, BAY43-9006) | 17.3 | 15.3 | 22.4 | 22.4 | 12.8 | 9.7 |
5 reviews available for niacinamide and Carcinoma, Papillary
| Article | Year |
|---|---|
Sorafenib and thyroid cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carci | 2013 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2009 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Huma | 2009 |
Sorafenib: rays of hope in thyroid cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interact | 2010 |
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Human | 2004 |
5 trials available for niacinamide and Carcinoma, Papillary
| Article | Year |
|---|---|
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; D | 2015 |
Motesanib diphosphate in progressive differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agent | 2008 |
Motesanib diphosphate in progressive differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agent | 2008 |
Motesanib diphosphate in progressive differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agent | 2008 |
Motesanib diphosphate in progressive differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agent | 2008 |
Sorafenib: rays of hope in thyroid cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interact | 2010 |
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disea | 2011 |
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Aged, 80 and over; Antineoplastic Agents; Benz | 2012 |
20 other studies available for niacinamide and Carcinoma, Papillary
| Article | Year |
|---|---|
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcin | 2018 |
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy | 2018 |
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; | 2014 |
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; | 2014 |
Response to sorafenib treatment in advanced metastatic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; | 2014 |
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Dis | 2014 |
Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Autoantigens; Carcinoma, Papillary; Cell Cycle; Cell Lin | 2015 |
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Cell Line, Tumor; Cell Prol | 2008 |
The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
Topics: Adolescent; Benzenesulfonates; Carcinoma, Papillary; Child; Female; Humans; Iodine Radioisotopes; Lu | 2009 |
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, | 2010 |
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
Topics: Acute Coronary Syndrome; Benzamides; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Fatal Outco | 2011 |
The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Neopla | 2011 |
[Long-standing differentiated thyroid carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Carcinoma, Large Cell; Carcinoma, Papillar | 2012 |
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Ou | 2012 |
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cel | 2013 |
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papill | 2012 |
BRAF is a therapeutic target in aggressive thyroid carcinoma.
Topics: Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Humans; Male; Mice; | 2006 |
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2008 |
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2007 |